Free shipping on orders over $200·99%+ purity — verified by independent US labs·Refer a colleague, earn $50 in credits·Free shipping on orders over $200·99%+ purity — verified by independent US labs·Refer a colleague, earn $50 in credits·
Return to Directory

Cagrilintide

Technical Monograph

Cagrilintide is a long-acting, synthetic mimetic of the endogenous pancreatic polypeptide hormone amylin. Concurrently secreted alongside insulin by pancreatic beta cells, amylin plays a pivotal role in glycemic regulation and satiety. Cagrilintide has been deeply engineered for vastly superior half-life and unique, non-incretin-based mechanism of caloric control.

Mechanism of Action

The mechanism acts wholly independent of GLP-1, GIP, or GCG pathways. Cagrilintide selectively targets and binds amylin and calcitonin receptors located deeply within the central nervous system (specifically the area postrema and nucleus tractus solitarius). This activation significantly delays gastric emptying, rigidly suppresses post-prandial glucagon secretion, and projects powerful, unrelenting satiety signals.

Pharmacological Detail

Direct agonist of the amylin receptor complex (calcitonin receptor bound to receptor activity-modifying proteins RAMP1, RAMP2, or RAMP3).

Pharmacodynamics

Extremely potent suppression of caloric intake via central vagal and hindbrain stimulation. Acts natively as a post-prandial satiation brake.

Pharmacokinetics

Attached to a large, specialized fatty acid and hydrophilic linker, it highly binds to systemic albumin, resulting in an estimated terminal half-life stretching from 150 to 180 hours.

Preclinical Observations & In Vitro Data

Extensive preclinical data supports its role as the premiere non-incretin weight management peptide.

Preclinical (Rat): Dose-dependent absolute reductions in food intake averaging 45% vs robust placebo controls.
Preclinical (Diet-Induced Obesity Models): Produced 15-20% total mass reductions as a monotherapy. Demonstrated profound synergistic weight reduction when combined with semaglutide.

Observed Timeline of Action

TimeframePharmacological Effect
24-72 hoursPeak plasma concentration resulting in sudden, profound satiation.
1-2 weeksInitial mass reduction primarily driven by significantly decelerated gastric motility.

Abstract Highlights

  • Functions via entirely distinct neural pathways compared to traditional incretin (GLP-1) mimetics
  • Provides massive synergistic potential when co-administered with GLP-1 agents
  • Strongly preserves lean mass parameters compared to highly catabolic legacy lipolytic therapies
  • Slows total intestinal transit time, blunting maximal glucose excursions following feeding

References

Kruse T, et al. (2021)."Cagrilintide, a novel long-acting amylin analogue for weight management."Diabetes, Obesity and Metabolism.

Chemical Specifications

3312.6 g/mol
C144H236N42O46
KCNTATCVLGRLSQELHRLQTYPRTNTGSNTY

Material Handling & Stability

Laboratory StorageLyophilized powder: Store securely at -20°C.
Aqueous StabilityReconstituted: Stable at 2-8°C utilizing strict bacteriostatic agents. Estimated viable lifespan of 30 days.

Strict Notice

THIS COMPOUND IS PRODUCED FOR LABORATORY RESEARCH PURPOSES ONLY. NOT FOR HUMAN CONSUMPTION. MATERIAL DATA SHEETS AND LABORATORY GUIDELINES SHOULD BE CONSULTED PRIOR TO HANDLING.